Incidence of SPMs in patients treated with lenalidomide-based therapy
| . | Treatment duration . | |||||
|---|---|---|---|---|---|---|
| < 12 mo (n = 3149) . | ≥ 12 mo (n = 697) . | ≥ 18 mo (n = 450) . | ≥ 24 mo (n = 313) . | ≥ 36 mo (n = 130) . | All patients (N = 3846) . | |
| SPM IR | 2.03 | 2.12 | 2.13 | 2.35 | 2.45 | 2.08 |
| Patient-years | 1281.20 | 1463.35 | 1175.78 | 937.28 | 490.52 | 2744.55 |
| 95% CI | 1.38-2.98 | 1.49-3.01 | 1.44-3.15 | 1.55-3.56 | 1.39-4.31 | 1.60-2.60 |
| . | Treatment duration . | |||||
|---|---|---|---|---|---|---|
| < 12 mo (n = 3149) . | ≥ 12 mo (n = 697) . | ≥ 18 mo (n = 450) . | ≥ 24 mo (n = 313) . | ≥ 36 mo (n = 130) . | All patients (N = 3846) . | |
| SPM IR | 2.03 | 2.12 | 2.13 | 2.35 | 2.45 | 2.08 |
| Patient-years | 1281.20 | 1463.35 | 1175.78 | 937.28 | 490.52 | 2744.55 |
| 95% CI | 1.38-2.98 | 1.49-3.01 | 1.44-3.15 | 1.55-3.56 | 1.39-4.31 | 1.60-2.60 |